Casma Therapeutics
Latest round
- Series C
Last raised
- Nov 2022
Total raised
- $121M
Investors
- 10
About Casma Therapeutics
Casma Therapeutics, Inc.Founded in 2018 and based in Cambridge, US, Casma Therapeutics, Inc. specializes in therapeutics aimed at reprogramming the autophagy pathway.00 mn. The firm’s leadership includes CEO Frank Gentile and Keith Dionne, with James Hurley recognized as a key founder.Casma Therapeutics specializes in innovative therapeutics focused on reprogramming the autophagy pathway to degrade disease targets. Their core product offerings revolve around the proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform, which facilitates target-specific autophagic degradation of diverse disease-causing elements inside cells. This technology allows for the elimination of larger and more complex targets, such as organelles and protein aggregates, which traditional therapies may overlook. The end uses for these products span therapeutic applications in oncology, inflammation, neurodegeneration, and metabolic disorders, aiming to either arrest or reverse disease progression.Casma Therapeutics generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and research institutions. These partnerships typically involve licensing agreements where clients can access the PHLYT™ platform for their drug discovery efforts. Revenue is derived from milestone payments tied to the successful development of therapies using Casma's technology, as well as potential royalties once products reach commercial viability. The transactional structure is designed to incentivize long-term collaboration, focusing on both B2B interactions within the pharmaceutical sector.In November 2022, Casma Therapeutics, Inc. The company plans to utilize these funds to advance its lead program for MYD88 mutant lymphoma through preclinical studies and into IND-enabling studies. Future growth targets include the launch of new products based on the PHLYT™ platform, with expansion plans primarily aimed at enhancing their market presence in both North America and Europe.
Who invested in Casma Therapeutics
10 investors across 3 rounds
See all investors in Casma Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Casma Therapeutics
Who invested in Casma Therapeutics?
Casma Therapeutics has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Casma Therapeutics raised?
Casma Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Casma Therapeutics last raise money?
Casma Therapeutics's most recent round on record is a Series C, in Nov 2022.
What does Casma Therapeutics do?
Casma Therapeutics is a biotechnology company.
Where is Casma Therapeutics headquartered?
Casma Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Casma Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Casma Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Casma Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.